Tsai, H.-C.; Ho, K.-C.; Chen, S.-H.; Tseng, J.-R.; Yang, L.-Y.; Lin, K.-J.; Cheng, J.-C.; Liou, M.-J.
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal. Diagnostics 2022, 12, 221.
https://doi.org/10.3390/diagnostics12010221
AMA Style
Tsai H-C, Ho K-C, Chen S-H, Tseng J-R, Yang L-Y, Lin K-J, Cheng J-C, Liou M-J.
Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal. Diagnostics. 2022; 12(1):221.
https://doi.org/10.3390/diagnostics12010221
Chicago/Turabian Style
Tsai, Hsi-Chen, Kung-Chu Ho, Shih-Hsin Chen, Jing-Ren Tseng, Lan-Yan Yang, Kun-Ju Lin, Ju-Chin Cheng, and Miaw-Jene Liou.
2022. "Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal" Diagnostics 12, no. 1: 221.
https://doi.org/10.3390/diagnostics12010221
APA Style
Tsai, H. -C., Ho, K. -C., Chen, S. -H., Tseng, J. -R., Yang, L. -Y., Lin, K. -J., Cheng, J. -C., & Liou, M. -J.
(2022). Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal. Diagnostics, 12(1), 221.
https://doi.org/10.3390/diagnostics12010221
